ESR1 and breast carcinoma: It is therefore clear that ER+ breast cancers continue to pose therapeutic challenges and there is an urgent need to develop novel therapeutics to treat them (Massarweh and Schiff, 2006[53]; Gonzalez-Angulo et al., 2007[30]; Moiseenko et al., 2017[56]).